These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 24243529

  • 21. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS, Kansal AR, Gandhi PK, Cragin L, Brand SB, Pfarr E, Fahrbach K, Ustyugova A.
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [Abstract] [Full Text] [Related]

  • 22. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
    Del Prato S, Giorgino F, Szafranski K, Poon Y.
    Diabetes Obes Metab; 2024 Sep; 26(9):3633-3641. PubMed ID: 38853717
    [Abstract] [Full Text] [Related]

  • 23. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
    Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P.
    Clin Drug Investig; 2012 Mar 01; 32(3):189-202. PubMed ID: 22292415
    [Abstract] [Full Text] [Related]

  • 24. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B.
    J Med Econ; 2020 Feb 01; 23(2):193-203. PubMed ID: 31613199
    [Abstract] [Full Text] [Related]

  • 25. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar 01; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 26. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A, Buchholt AT, El Khoury AC, Kamal A, Taieb V.
    Curr Med Res Opin; 2017 Jun 01; 33(6):1155-1163. PubMed ID: 28323512
    [Abstract] [Full Text] [Related]

  • 27. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis.
    Cortesi PA, Antonazzo IC, Palladino P, Gnesi M, Mele S, D'Amelio M, Zanzottera Ferrari E, Mazzaglia G, Mantovani LG.
    Acta Diabetol; 2024 Aug 01; 61(8):1017-1028. PubMed ID: 38634912
    [Abstract] [Full Text] [Related]

  • 28. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
    Tisdale RL, Cusick MM, Aluri KZ, Handley TJ, Joyner AKC, Salomon JA, Chertow GM, Goldhaber-Fiebert JD, Owens DK.
    J Gen Intern Med; 2022 Oct 01; 37(13):3380-3387. PubMed ID: 35137296
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N, Calvachi P, Raber I, Liu CL, Bellows BK, Hernandez I, Shen C, Gavin MC, Garan AR, Kazi DS.
    JAMA Netw Open; 2021 Jul 01; 4(7):e2114501. PubMed ID: 34313742
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.
    Curr Med Res Opin; 2009 May 01; 25(5):1273-84. PubMed ID: 19366302
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 May 01; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.
    Curr Med Res Opin; 2008 May 01; 24(5):1417-28. PubMed ID: 18400145
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S, Deng X, Ma Y, Li Z, Wang Y, Wang Y.
    Appl Health Econ Health Policy; 2021 Jan 01; 19(1):69-79. PubMed ID: 32783086
    [Abstract] [Full Text] [Related]

  • 40. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
    Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT.
    Diabetes Care; 2009 Sep 01; 32(9):1656-62. PubMed ID: 19528367
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.